

## PACIFIC EDGE FULL YEAR RESULT TO BE ANNOUNCED 26 MAY 2022

Cancer diagnostics company Pacific Edge Limited (NZX:PEB) advises that its full year results for the 12 months to 31 March 2022 (FY22) will be released on Thursday 26 May 2022, prior to 10am.

This will be followed by an Investor and Analyst conference call at 11.30am (NZST). This investor briefing will be available via webcast (presentation slides and audio only) or 'audio only' service. Please follow the instructions outlined below to access the event.

### Webcast Instructions

To join the investor briefing online, click on the link below to view, listen to and ask written questions on the Investor presentation directly from your laptop, tablet or mobile device. Please note if you are using the Webcast option, it is not necessary to dial into the audio conference as well. Audio will stream through your selected device, so be sure to have headphones or your volume turned up. If you have technical difficulties, please click the "Listen by Phone" button on the webcast player and dial the number provided.

To attend the webcast, please register at the following link:

[https://event.webcasts.com/starthere.jsp?ei=1543589&tp\\_key=6e86aa4eb9](https://event.webcasts.com/starthere.jsp?ei=1543589&tp_key=6e86aa4eb9)

### Audio only – Participant Access Instructions

For the 'audio only' option, you can access the investor briefing from your phone. Please join the briefing 5-10 minutes prior to the start time. Please provide your details when prompted and the event passcode: **704484**. It is not necessary to dial into the audio conference, unless you are unable to join the webcast URL.

New Zealand, toll free:	0800 423 972
New Zealand, Auckland:	+64 (0)9 9133 624
Australia, toll free:	1800 590 693
Australia, Brisbane:	+61 (0)7 3105 0937
Australia, Melbourne:	+61 (0)3 8317 0929
Australia, Sydney:	+61 (0)2 7250 5438
USA/Canada, toll free:	800 289 0462
USA, Los Angeles:	+1 323 794 2442
Singapore, toll free:	800 120 7297
Singapore, local:	+65 6703 6913
Hong Kong, toll free:	800 961 113
Hong Kong, local:	+852 3008 1533

### Questions

Questions can be submitted online in writing via the Webcast platform or verbally via the audio call system when prompted.

The webcast will be available at the above link for 12 months following the event.

If you have any queries regarding the results announcement or the conference call, please contact Stacey Stanley on 03 479 5807 or [stacey.stanley@pelnz.com](mailto:stacey.stanley@pelnz.com).

ENDS

Company Announcement  
3 May 2022



**Approved for release by:**

Pete Meintjes  
Chief Executive Officer  
Pacific Edge Ltd  
P: +64 (3) 479 5800

**OVERVIEW** [www.pacifedge.co.nz](http://www.pacifedge.co.nz) [www.pacifedgedx.com](http://www.pacifedgedx.com)

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialisation of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

**ABOUT CXBLADDER** [www.cxbladder.com](http://www.cxbladder.com)

Cxbladder is a non-invasive genomic urine test optimized for the detection and management of bladder cancer. The Cxbladder evidence portfolio developed over the past 14 years includes more than 20 peer reviewed publications for primary detection, surveillance, adjudication of atypical urine cytology and equivocal cystoscopy. Cxbladder is the focal point of numerous ongoing and planned clinical studies to generate an ever-increasing body of clinical utility evidence supporting adoption and use in the clinic to improve patient health outcomes. Cxbladder is reimbursed by CMS and has been trusted by over 2,000 US urologists in the diagnosis and management of more than 80,000 patients, including the option for in-home sample collection. In New Zealand, Cxbladder is accessible to 70% of the population via public healthcare and all residents have the option of buying the test online.